Cargando…

Vascular Calcification and Renal Bone Disorders

At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and bone composition start to change. This alteration is known as chronic kidney disease-mineral bone disorder (CKD-MBD). It is well known that the bone turnover disorder is the most common complication of CKD-MBD. B...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Kuo-Cheng, Wu, Chia-Chao, Yen, Jen-Fen, Liu, Wen-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127293/
https://www.ncbi.nlm.nih.gov/pubmed/25136676
http://dx.doi.org/10.1155/2014/637065
_version_ 1782330016553500672
author Lu, Kuo-Cheng
Wu, Chia-Chao
Yen, Jen-Fen
Liu, Wen-Chih
author_facet Lu, Kuo-Cheng
Wu, Chia-Chao
Yen, Jen-Fen
Liu, Wen-Chih
author_sort Lu, Kuo-Cheng
collection PubMed
description At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and bone composition start to change. This alteration is known as chronic kidney disease-mineral bone disorder (CKD-MBD). It is well known that the bone turnover disorder is the most common complication of CKD-MBD. Besides, CKD patients usually suffer from vascular calcification (VC), which is highly associated with mortality. Many factors regulate the VC mechanism, which include imbalances in serum calcium and phosphate, systemic inflammation, RANK/RANKL/OPG triad, aldosterone, microRNAs, osteogenic transdifferentiation, and effects of vitamins. These factors have roles in both promoting and inhibiting VC. Patients with CKD usually have bone turnover problems. Patients with high bone turnover have increase of calcium and phosphate release from the bone. By contrast, when bone turnover is low, serum calcium and phosphate levels are frequently maintained at high levels because the reservoir functions of bone decrease. Both of these conditions will increase the possibility of VC. In addition, the calcified vessel may secrete FGF23 and Wnt inhibitors such as sclerostin, DKK-1, and secreted frizzled-related protein to prevent further VC. However, all of them may fight back the inhibition of bone formation resulting in fragile bone. There are several ways to treat VC depending on the bone turnover status of the individual. The main goals of therapy are to maintain normal bone turnover and protect against VC.
format Online
Article
Text
id pubmed-4127293
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41272932014-08-18 Vascular Calcification and Renal Bone Disorders Lu, Kuo-Cheng Wu, Chia-Chao Yen, Jen-Fen Liu, Wen-Chih ScientificWorldJournal Review Article At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and bone composition start to change. This alteration is known as chronic kidney disease-mineral bone disorder (CKD-MBD). It is well known that the bone turnover disorder is the most common complication of CKD-MBD. Besides, CKD patients usually suffer from vascular calcification (VC), which is highly associated with mortality. Many factors regulate the VC mechanism, which include imbalances in serum calcium and phosphate, systemic inflammation, RANK/RANKL/OPG triad, aldosterone, microRNAs, osteogenic transdifferentiation, and effects of vitamins. These factors have roles in both promoting and inhibiting VC. Patients with CKD usually have bone turnover problems. Patients with high bone turnover have increase of calcium and phosphate release from the bone. By contrast, when bone turnover is low, serum calcium and phosphate levels are frequently maintained at high levels because the reservoir functions of bone decrease. Both of these conditions will increase the possibility of VC. In addition, the calcified vessel may secrete FGF23 and Wnt inhibitors such as sclerostin, DKK-1, and secreted frizzled-related protein to prevent further VC. However, all of them may fight back the inhibition of bone formation resulting in fragile bone. There are several ways to treat VC depending on the bone turnover status of the individual. The main goals of therapy are to maintain normal bone turnover and protect against VC. Hindawi Publishing Corporation 2014 2014-07-17 /pmc/articles/PMC4127293/ /pubmed/25136676 http://dx.doi.org/10.1155/2014/637065 Text en Copyright © 2014 Kuo-Cheng Lu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lu, Kuo-Cheng
Wu, Chia-Chao
Yen, Jen-Fen
Liu, Wen-Chih
Vascular Calcification and Renal Bone Disorders
title Vascular Calcification and Renal Bone Disorders
title_full Vascular Calcification and Renal Bone Disorders
title_fullStr Vascular Calcification and Renal Bone Disorders
title_full_unstemmed Vascular Calcification and Renal Bone Disorders
title_short Vascular Calcification and Renal Bone Disorders
title_sort vascular calcification and renal bone disorders
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127293/
https://www.ncbi.nlm.nih.gov/pubmed/25136676
http://dx.doi.org/10.1155/2014/637065
work_keys_str_mv AT lukuocheng vascularcalcificationandrenalbonedisorders
AT wuchiachao vascularcalcificationandrenalbonedisorders
AT yenjenfen vascularcalcificationandrenalbonedisorders
AT liuwenchih vascularcalcificationandrenalbonedisorders